Logo image of EKSO

EKSO BIONICS HOLDINGS INC (EKSO) Stock Price, Quote, News and Overview

NASDAQ:EKSO - Nasdaq - US2826443010 - Common Stock - Currency: USD

3.59  -0.31 (-7.95%)

Premarket: 3.41 -0.18 (-5.01%)

EKSO Quote, Performance and Key Statistics

EKSO BIONICS HOLDINGS INC

NASDAQ:EKSO (6/18/2025, 8:00:01 PM)

Premarket: 3.41 -0.18 (-5.01%)

3.59

-0.31 (-7.95%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
Statistics
52 Week High22.95
52 Week Low3.46
Market Cap104.25M
Shares29.04M
Float1.78M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)07-28 2025-07-28/amc
IPO04-10 2013-04-10


EKSO short term performance overview.The bars show the price performance of EKSO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40 -50

EKSO long term performance overview.The bars show the price performance of EKSO in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of EKSO is 3.59 USD. In the past month the price decreased by -17.64%. In the past year, price decreased by -77.84%.

EKSO BIONICS HOLDINGS INC / EKSO Daily stock chart

EKSO Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 27.7 230.37B
ISRG INTUITIVE SURGICAL INC 66.69 182.61B
BSX BOSTON SCIENTIFIC CORP 37.54 149.97B
SYK STRYKER CORP 29.79 142.65B
MDT MEDTRONIC PLC 15.59 109.95B
BDX BECTON DICKINSON AND CO 11.97 48.32B
EW EDWARDS LIFESCIENCES CORP 28.45 43.40B
IDXX IDEXX LABORATORIES INC 45.6 42.13B
RMD RESMED INC 27.63 36.79B
GEHC GE HEALTHCARE TECHNOLOGY 15.63 32.92B
DXCM DEXCOM INC 49.1 31.76B
STE STERIS PLC 25.29 23.21B

About EKSO

Company Profile

EKSO logo image Ekso Bionics Holdings, Inc. engages in the design, development and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company is headquartered in San Rafael California, California and currently employs 61 full-time employees. The company went IPO on 2013-04-10. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. The company operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. Additionally, the devices assist people with a variety of upper extremity disabilities and enable industrial employees to perform challenging repetitive tasks for extended periods.

Company Info

EKSO BIONICS HOLDINGS INC

101 Glacier Point, Suite A

San Rafael California CALIFORNIA 94804 US

CEO: Jack Peurach

Employees: 64

EKSO Company Website

EKSO Investor Relations

Phone: 15109841761

EKSO BIONICS HOLDINGS INC / EKSO FAQ

What is the stock price of EKSO BIONICS HOLDINGS INC today?

The current stock price of EKSO is 3.59 USD. The price decreased by -7.95% in the last trading session.


What is the ticker symbol for EKSO BIONICS HOLDINGS INC stock?

The exchange symbol of EKSO BIONICS HOLDINGS INC is EKSO and it is listed on the Nasdaq exchange.


On which exchange is EKSO stock listed?

EKSO stock is listed on the Nasdaq exchange.


What is EKSO BIONICS HOLDINGS INC worth?

EKSO BIONICS HOLDINGS INC (EKSO) has a market capitalization of 104.25M USD. This makes EKSO a Micro Cap stock.


How many employees does EKSO BIONICS HOLDINGS INC have?

EKSO BIONICS HOLDINGS INC (EKSO) currently has 64 employees.


What are the support and resistance levels for EKSO BIONICS HOLDINGS INC (EKSO) stock?

EKSO BIONICS HOLDINGS INC (EKSO) has a resistance level at 3.99. Check the full technical report for a detailed analysis of EKSO support and resistance levels.


Is EKSO BIONICS HOLDINGS INC (EKSO) expected to grow?

The Revenue of EKSO BIONICS HOLDINGS INC (EKSO) is expected to decline by -1.46% in the next year. Check the estimates tab for more information on the EKSO EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy EKSO BIONICS HOLDINGS INC (EKSO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does EKSO BIONICS HOLDINGS INC (EKSO) stock pay dividends?

EKSO does not pay a dividend.


When does EKSO BIONICS HOLDINGS INC (EKSO) report earnings?

EKSO BIONICS HOLDINGS INC (EKSO) will report earnings on 2025-07-28, after the market close.


What is the Price/Earnings (PE) ratio of EKSO BIONICS HOLDINGS INC (EKSO)?

EKSO BIONICS HOLDINGS INC (EKSO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.13).


EKSO Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

EKSO Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to EKSO. EKSO may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

EKSO Financial Highlights

Over the last trailing twelve months EKSO reported a non-GAAP Earnings per Share(EPS) of -4.13. The EPS decreased by -325.77% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -39.52%
ROE -85.03%
Debt/Equity 0.28
Chartmill High Growth Momentum
EPS Q2Q%-800%
Sales Q2Q%-10.14%
EPS 1Y (TTM)-325.77%
Revenue 1Y (TTM)-2.06%

EKSO Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to EKSO. The Buy consensus is the average rating of analysts ratings from 8 analysts.

For the next year, analysts expect an EPS growth of 85.49% and a revenue growth -1.46% for EKSO


Ownership
Inst Owners10.69%
Ins Owners6.58%
Short Float %N/A
Short Ratio0.44
Analysts
Analysts82.5
Price TargetN/A
EPS Next Y85.49%
Revenue Next Year-1.46%